Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases

Vaccine
Paolo BonanniK Banz

Abstract

An economic evaluation of universal varicella vaccination in Italy was performed to assess the potential clinical and economic effects of three different strategies versus no vaccination. By means of the EVITA model, vaccination with two doses in toddlers only (1-1.5 years), adolescents only (13 years) and toddlers with adolescents catch-up programmes were simulated. All universal varicella vaccination strategies including toddlers (with or without an adolescent catch-up programme) turned out to be highly effective in reducing the burden of disease due to varicella. In addition, they lead to significant net savings from the societal perspective but to higher costs compared to return of investment from National Health Service perspective. The huge economic burden of hospitalised uncomplicated varicella cases registered in Italy can partially explain these highly beneficial findings for the societal perspective. Overall, our analysis confirmed the favourable clinical and economic impact of routine varicella vaccination with two doses of vaccine in Italy.

References

Sep 1, 1996·Infectious Disease Clinics of North America·M E Halloran
Dec 9, 1995·PharmacoEconomics·P Van Damme, P Beutels
Feb 24, 2001·Epidemiology and Infection·M BrissonG De Serres
Jul 27, 2001·Epidemiology and Infection·G GabuttiUNKNOWN Serological Study Group
Jul 13, 2002·Epidemiology and Infection·M L Ciofi degli AttiS Salmaso
Nov 25, 2003·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Thomas HammerschmidtKurt Banz
Mar 12, 2004·The Pediatric Infectious Disease Journal·Justen H PasswellLiat Lerner-Geva
Aug 19, 2004·Vaccine·Nancy ThiryPierre Van Damme
Aug 27, 2004·PharmacoEconomics·Laurent CoudevilleBenoit Dervaux
Apr 29, 2005·The New England Journal of Medicine·Raffaella GiacchinoElio Castagnola

❮ Previous
Next ❯

Citations

May 30, 2009·BMC Medicine·Paolo BonanniPeter Wutzler
Nov 19, 2011·BMC Infectious Diseases·Judith H Wolleswinkel-van den BoschSander C Fortanier
Jul 14, 2010·The Journal of Allergy and Clinical Immunology·Jonathan I SilverbergTamar A Smith-Norowitz
Jan 1, 2015·Journal of Market Access & Health Policy·Walter Ricciardi, Mondher Toumi
Aug 25, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Matteo RuggeriAmerico Cicchetti
Jan 1, 2015·Journal of Market Access & Health Policy·Maarten J PostmaAlexandra Brandão
Jul 5, 2013·Human Vaccines & Immunotherapeutics·Brigid UnimGiuseppe La Torre
Oct 22, 2011·Vaccine·Francesca PozzaLeonardo Emberti Gialloreti
Jan 29, 2013·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Ewelina GowinMichał Michalak
Jun 24, 2016·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Sara BoccaliniAngela Bechini
Jan 21, 2010·Cadernos de saúde pública·Patrícia Coelho de SoárezAna Marli Christovan Sartori
Apr 24, 2014·Therapeutic Advances in Vaccines·Orestis PapaloukasVassiliki Papaevangelou
Sep 25, 2020·Expert Review of Vaccines·Florence KauffmannPeter Wutzler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
K BanzP Wutzler
JAMA : the Journal of the American Medical Association
Fangjun ZhouAbigail Shefer
© 2022 Meta ULC. All rights reserved